120 related articles for article (PubMed ID: 23507546)
1. Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers.
Teefey P; Bou Zgheib N; Apte SM; Gonzalez-Bosquet J; Judson PL; Roberts WS; Lancaster JM; Wenham RM
Am J Obstet Gynecol; 2013 Jun; 208(6):501.e1-7. PubMed ID: 23507546
[TBL] [Abstract][Full Text] [Related]
2. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
3. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
4. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.
Dizon DS; Sill MW; Gould N; Rubin SC; Yamada SD; Debernardo RL; Mannel RS; Eisenhauer EL; Duska LR; Fracasso PM
Gynecol Oncol; 2011 Nov; 123(2):182-6. PubMed ID: 21820161
[TBL] [Abstract][Full Text] [Related]
5. Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
Chang YH; Lu CH; Yen MS; Lee WH; Chang Y; Chang WP; Chuang CM
Chin J Cancer; 2016 May; 35():45. PubMed ID: 27160669
[TBL] [Abstract][Full Text] [Related]
6. Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer.
Battelli C; Campo M; Buss MK; Awtrey CS; Konstantinopoulos PA
Chemotherapy; 2013; 59(4):251-9. PubMed ID: 24457572
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
[TBL] [Abstract][Full Text] [Related]
8. Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients.
Becker DA; Leath CA; Walters-Haygood CL; Smith BQ; Bevis KS
Am J Clin Oncol; 2019 Jan; 42(1):12-16. PubMed ID: 29782365
[TBL] [Abstract][Full Text] [Related]
9. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
Moore KN; Miller A; Bell-McGuinn KM; Schilder RJ; Walker JL; O'Cearbhaill RE; Guntupalli SR; Armstrong DK; Hagemann AR; Gray HJ; Duska LR; Mathews CA; Chen A; O'Malley D; Gordon S; Fracasso PM; Aghajanian C
Gynecol Oncol; 2020 Jan; 156(1):13-22. PubMed ID: 31708167
[TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Kelly MG; Mor G; Husband A; O'Malley DM; Baker L; Azodi M; Schwartz PE; Rutherford TJ
Int J Gynecol Cancer; 2011 May; 21(4):633-9. PubMed ID: 21412168
[TBL] [Abstract][Full Text] [Related]
12. Dose-dense approaches to ovarian cancer treatment.
Katsumata N
Curr Treat Options Oncol; 2015 May; 16(5):21. PubMed ID: 25859831
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.
Bruixola G; Domingo S; Díaz R; Caballero J; Palomar L; De La Cueva H; Santaballa A
Int J Gynecol Cancer; 2015 Feb; 25(2):214-21. PubMed ID: 25415075
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.
Oaknin A; Roda D; González-Martín A; Chiva L; García-Donas J; de Juan A; Redondo A; Martínez S; García Y; Catot S; Ponce J; Del Campo JM; Cervantes A; Poveda A
Int J Gynecol Cancer; 2011 Aug; 21(6):1048-55. PubMed ID: 21738038
[TBL] [Abstract][Full Text] [Related]
16. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
[TBL] [Abstract][Full Text] [Related]
17. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
18. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.
Konner JA; Grabon DM; Gerst SR; Iasonos A; Thaler H; Pezzulli SD; Sabbatini PJ; Bell-McGuinn KM; Tew WP; Hensley ML; Spriggs DR; Aghajanian CA
J Clin Oncol; 2011 Dec; 29(35):4662-8. PubMed ID: 22067389
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
